IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISORDERS

Compositions and methods for preventing and/or reducing amyloid deposition in a subject comprising treatment of a subject with a composition comprising a TLR4 agonist free of endotoxin are provided. Also provided is a TLR4 agonist free of endotoxin for preventing and/or reducing Alzheimer's dis...

Full description

Saved in:
Bibliographic Details
Main Authors HALLE, MAXIME, TRIBOUT-JOVER, PASCALE, PRIEELS, JEAN-PAUL, PALMANTIER, REMI, LAROCQUE, DANIEL
Format Patent
LanguageEnglish
French
Published 03.05.2012
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compositions and methods for preventing and/or reducing amyloid deposition in a subject comprising treatment of a subject with a composition comprising a TLR4 agonist free of endotoxin are provided. Also provided is a TLR4 agonist free of endotoxin for preventing and/or reducing Alzheimer's disease. Pharmaceutical compositions consisting of, or consisting essentially of, an aminoalkyl glucosaminide phosphate, 3D-MPL, AS01B or an AGP in combination with an oil in water emulsion are also provided. Cette invention concerne des compositions et des méthodes permettant de prévenir et/ou de réduire les dépôts amyloïdes chez un sujet, lesdites méthodes consistant à traiter ledit sujet avec une composition comprenant un agoniste des TLR4 dépourvu d'endotoxine. L'invention concerne également un agoniste des TLR4 dépourvu d'endotoxine permettant de prévenir et/ou de réduire les symptômes de la maladie d'Alzheimer. L'invention concerne par ailleurs des compositions pharmaceutiques constituées, ou constituées essentiellement de phosphate d'aminoalkyl glucosaminide (AGP), 3D-MPL et AS01B, ou d'un AGP en association avec une émulsion huile dans l'eau.
Bibliography:Application Number: WO2011EP68909